Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca (AZ) and development partner Avillion, has been approved by the US Food and Drug Administration (FDA). A first-in-class ...

AstraZeneca and its development ... with a history of asthma exacerbations and uncontrolled asthma receiving currently approved inhaled treatment versus placebo. The trial showed annual asthma ...

LONDON — AstraZeneca’s AZN.L Fasenra, an injectable treatment for severe asthma, is more effective during attacks than the oral steroid that has been the standard of care for 50 years ...

Weather conditions in the United Arab Emirates (UAE) trigger asthma. While most adults are given medication to deal with such ailments, children often need emergency nebulisation treatments that are ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for 50% of the company’s total revenue by 2030.

asthma-related deaths, and hospitalization. DCGI approves AstraZeneca's injection 'Fasenra' for treatment of severe eosinophilic asthma Eosinophilic asthma (EA) is a type of asthma that is ...

Today, 70% of African asthma and COPD sufferers are undiagnosed and the WHO forecasts a 20% increase in respiratory related deaths in the next 10 years. AstraZeneca asked us to create awareness and ...

are positioned for indication expansion into severe asthma and chronic obstructive pulmonary disorder (COPD), respectively, during 2025. Sarin said AstraZeneca’s capital allocation priorities ...